North East and North Cumbria
ICS Formulary
2 Cardiovascular system
02-12 Other lipid modifying agents
Evinacumab
Evkeeza
®
Formulary
150 mg/ml concentrate for solution for infusion
Approved for treating homozygous familial hypercholesterolaemia (HoFH) in people 12 years and over in line with NICE
NICE TA1002 : Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over
Links
Academic Health Science Network (North East and North Cumbria) - Atrial Fibrilation
MHRA Drug Safety Update (Dec 2010): Fibrates: first-line treatment not recommended
MHRA Drug Safety Update (Dec 2010): Fibrates: first-line treatment not recommended
MHRA Drug Safety Update (Dec 2014): Simvastatin: dose limitations with concomitant amlodipine or diltiazem
MHRA Drug Safety Update (May 2014): Statins: benefits and risks
NICE NG148: Acute kidney injury: prevention, detection and management
NICE NG185: Acute coronary syndromes
NICE NG191: COVID-19 rapid guideline: managing COVID-19
NICE NG238: Cardiovascular disease: risk assessment and reduction, including lipid modification
NICE TA 733 - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia
NICE TA1002 : Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over
NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
NICE TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
NICE TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
NICE TA805: Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides
Northern England Evaluation and Lipid Intensification (NEELI) Guideline
Key
Full Site